STC-15 is the first METTL3 inhibitor to enter clinical
development
Clinical data will include safety, pharmacology, target
modulation, and clinical activity
CAMBRIDGE, England, May 24, 2024
/PRNewswire/ -- STORM Therapeutics Ltd. (STORM), the clinical stage
company pioneering cellular reprogramming through RNA modifications
to treat disease, today announces that it will be presenting
interim clinical data on its first-in-class lead product, STC-15 at
the upcoming American Society of Clinical Oncology (ASCO) Annual
Meeting, taking place in Chicago,
US from May 31 to June 4, 2024.
The poster presentation, entitled 'Phase 1 Dose Escalation
and Cohort Expansion Study Evaluating Safety, PK, PD and Clinical
Activity of STC-15, a METTL3 Inhibitor, in Patients with Advanced
Malignancies', describes findings from STORM's ongoing dose
escalation and expansion Phase 1 clinical study to evaluate STC-15,
an oral and highly selective small molecule inhibitor of METTL3, in
advanced cancer patients. These interim results will focus on
safety, pharmacokinetics, target modulation and tumor assessments
to support future clinical studies. STC-15 is the first molecule
specifically targeting an RNA methyltransferase enzyme to enter
clinical development.
Preclinical data has demonstrated that METTL3 inhibition
stimulates immune cells and activates interferon pathways, leading
to the destruction of tumor cells. The poster presentation will
detail the study design, patient demographics, safety data,
pharmacokinetics, METTL3 target engagement, mechanistic biomarker
data, and assessments of clinical activity.
Details of the poster presentation are as follow:
Poster Title: Phase 1 dose escalation and cohort
expansion study evaluating safety, PK, PD and clinical activity of
STC-15, a METTL3 inhibitor, in patients with advanced
malignancies
Presenter: Justin Moser at HonorHealth Research
Institute
Authors: Justin
Moser[1], Kyriakos
Papadopoulos[2], Jordi
Rodon Ahnert[3], Yaara
Ofir-Rosenfeld[4], Josefin-Beate
Holz[4]
Organizations:
[1]HonorHealth Research Institute, [2]START
San Antonio, [3]The
University of Texas MD Anderson Cancer
Center, [4]Storm Therapeutics Ltd
Poster Session: Developmental
Therapeutics—Immunotherapy
Session Date and Time: Saturday June 1, 2024,
9:00 AM - 12:00 PM CDT
Poster Board Number: 65
Abstract Presentation Number: 2586
The Abstract is available on the ASCO online itinerary planner
here, and on the STORM website here.
NOTES TO EDITORS
About STORM Therapeutics
STORM Therapeutics is a
clinical-stage biotechnology company pioneering cellular
reprogramming through RNA modifications to treat disease. Its world
leading understanding of RNA modifying enzymes (RME) has led to the
discovery of breakthrough small molecule drugs that precisely
reprogram cells through RNA biology for the treatment of cancer,
inflammation, viruses and CNS diseases.
STORM's lead product, STC-15, is the first RNA modifying enzyme
inhibitor to enter human clinical development. STC-15 is currently
being evaluated in a Phase 1 study in patients with advanced solid
tumors, establishing a data set allowing development in future
clinical studies. Preclinical data have revealed that METTL3
inhibition stimulates immune cells and activates interferon
pathways, leading to the destruction of tumor cells. Additional
preclinical studies have demonstrated enhanced anti-tumor
properties in combination with checkpoint inhibitors, supporting
clinical development in tumor types where an augmented immune
response may result in anti-cancer activity. STORM is building on
its first-mover advantage by positioning additional RME inhibitor
programs to advance into IND-track activities in 2024. STORM is
seeking partners to collaborate and accelerate development of these
novel drugs for disease applications outside of oncology.
STORM's specialist healthcare investors include M Ventures,
Pfizer Ventures, Taiho Ventures LLC, Seroba Life Sciences,
Cambridge Innovation Capital Limited, IP Group plc, UTokyo
Innovation Platform Co., Ltd. and the Fast Track Initiative
(FTI).
For more information, please visit www.stormtherapeutics.com
About STC-15
STORM's lead product, STC-15, is the
first RME inhibitor to enter human clinical evaluation. This agent
is an oral small molecule that inhibits METTL3, an RNA
methyltransferase implicated in oncology and other diseases.
Certain RNA methyltransferases are important regulators of RNA
sensing and innate immune activation and, as such, represent novel
immune-regulatory targets.
STC-15 has also been shown preclinically to inhibit tumor growth
through mechanisms involving anti-cancer immune responses, such as
changes in interferon signalling and synergy with T cell checkpoint
blockade.
STORM is studying the safety and pharmacology of STC-15 in a
Phase 1 clinical study in patients with solid tumors. Details of
the study can be found on clinicaltrials.gov under the
identifier NCT05584111.
About ASCO
Founded in 1964, the American Society of Clinical Oncology is
the world's leading professional organization for physicians and
oncology professionals caring for people with cancer.
View original
content:https://www.prnewswire.com/news-releases/storm-therapeutics-to-present-interim-phase-1-clinical-data-on-its-mettl3-rna-methyltransferase-inhibitor-stc-15-at-asco-2024-302154453.html
SOURCE STORM Therapeutics